Kornimate/medical-research-clean huggingface dataset:
ankle tracking training in stroke

Conditions: Stroke

Summary: the purpose of this study is to compare the improvement in ankle control and brain activation in subjects with stroke resulting from two different forms of telerehabilitation: tracking training, emphasizing accurate movements, versus movement training, involving simple movements. hypotheses: 1. the track group will show greater improvement in ankle range of motion compared to the move group. 2. the track group will show greater improvement in ankle tracking accuracy and greater changes in fmri (increase in relative volume of activation for ipsilesional sensorimotor cortex, increase in laterality index, and decrease in blood-oxygen-level-dependent (bold) signal intensity index) compared to move group. 3. the track group will show greater improvement in tracking accuracy at an untrained joint (knee) compared to the move group. 4. the track group will show greater improvement in standing balance. 5. the track group will show greater improvement in walking speed and ankle dorsiflexion during gait compared to the move group.


Eligibility criteria:
inclusion criteria: 1. single stroke with an ischemic infarct. 2. between 18 and 85 years of age. 3. time since stroke onset must be \>6 months. 4. cannot be receiving any rehabilitation therapy. 5. impaired ankle dorsiflexion/plantarflexion but at least 10 degrees of active motion. 6. cognition level must be at least 24 out of 30 on the mini-mental examination 7. able to ambulate at least 100 feet independently. training. exclusion criteria: 1. cannot have any neuromuscular disorder other than stroke that impairs ankle motion. 2. cannot have an executive function score on stroop interference test of \<37. 3. cannot have a score on the beck depression inventory of \>10. 4. cannot have ataxia, apraxia, receptive aphasia, hemi-neglect, or severe visual field cut . 5. cannot be pregnant nor have indwelling metal or medical devices incompatible with fmri.
shuntcheck performance characteristics in asymptomatic pseudotumor cerebri patients

Conditions: Pseudotumor Cerebri

Summary: the purpose of the study is to determine if the shuntcheck test can correctly identify flow or no flow in a ventriculoperitoneal shunt in patients with pseudotumor cerebri.

the purpose of the study is to determine if the shuntcheck test can correctly identify flow or no flow in a ventriculoperitoneal shunt in patients with pseudotumor cerebri. flow may be limited due to slit ventricles

Eligibility criteria:
inclusion criteria: * 18 years old or older adult men or women who possess a vp shunt placed for ptc; * capable of providing valid signed informed consent, or has a legal guardian, health care agent, or surrogate decision maker (according to local statutes, and collectively referred to as "surrogates" in this protocol) capable of providing valid, signed informed consent; * subjects will be asymptomatic visiting for routine care at 2-4 weeks post op exclusion criteria: * presence of multiple shunts, or presence of more than one distal shunt catheter (regardless of function) crossing the clavicle ipsilateral to the shunt with suspected obstruction; * shuntcheck test would interfere with standard patient care, or emergency shunt surgery that cannot be delayed is indicated; * presence of an interfering open wound or edema over any portion of the vp shunt.

Keywords: pseudotumor cerebri, ventriculoperitoneal shunt
brexpiprazole in patients with schizophrenia

Conditions: Schizophrenia

Summary: to determine the safety and efficacy of brexpiprazole during long-term treatment.


Eligibility criteria:
inclusion criteria: * the patient has completed the lead-in study 14644a. * the patient is judged to potentially benefit from 52-week treatment with brexpiprazole according to the clinical opinion of the investigator. * the patient agrees to protocol-defined use of effective contraception. exclusion criteria: * the patient has been diagnosed with a primary psychiatric disorder other than schizophrenia during study 14644a. * the patient has a clinically significant unstable illness diagnosed during study 14644a. * the patient, in the opinion of the investigator or according to columbia-suicide severity rating scale (c-ssrs), is at significant risk of suicide. * the patient has an abnormal ecg or other abnormal ecg tests that are, in the investigator's opinion, clinically significant. * the patient is, in the investigator's opinion, unlikely to comply with the protocol or is unsuitable for any reason. other inclusion and exclusion criteria may apply.
a comparison of saquinavir hard- and soft-gelatin capsules in hiv-infected patients

Conditions: HIV Infections

Summary: to compare the antiviral activity, safety, and pharmacokinetics of saquinavir hard gel capsule (hgc) formulation, to 1 of 3 doses of saquinavir soft gel capsule (sgc) formulation administered orally every 8 hours for 4 weeks.

patients are randomly assigned to one of the four treatment groups as follows: group 1: 10 patients receive saquinavir hgc. group 2: 10 patients receive saquinavir sgc. group 3: 30 patients receive saquinavir sgc at an intermediate dose. group 4: 30 patients receive saquinavir sgc at the highest study dose. upon completion of the initial 4 weeks, all patients may have the option to continue their originally-assigned therapy as monotherapy unless significant drug toxicity intervenes. if the analysis of the initial 4 week data identifies an optimal dose of saquinavir sgc, patients may have the option to change to this optimal dose in a treatment extension phase of the protocol. patients in this extension phase may choose to remain on monotherapy unless they experience significant drug toxicity, their cd4 count or hiv-rna levels return to baseline, until saquinavir is approved by the fda or study termination, whichever comes first. note: a washout \>= 28 days is required for patients on antiretroviral therapy.

Eligibility criteria:
inclusion criteria patients must have: * cd4 count of 100 to 500 cells/mm3. * greater than 20,000 hiv-rna copies/ml. exclusion criteria prior medication: excluded: prior treatment with protease inhibitors. required: * less than 8 weeks prior antiretroviral treatment (for at least 25% of patients). * at least 8 weeks prior antiretroviral treatment (for at least 25% of patients).

Keywords: drug administration schedule hiv protease inhibitors dosage forms saquinavir anti-hiv agents
effectiveness of the geriatric activation program pellenberg (gapp) on the geriatric rehabilitation ward

Conditions: Stroke; Hip Fractures; Abdominal Injury; Chronic Obstructive Pulmonary Disease

Summary: the aim of this study is to investigate the effectiveness of our developed week-treatment program gapp, on strength, balance, speed, functionality and cognition, with the main goal to achieve a better independence for activities of daily living (adl). each day of the week an exercise program of 45 minutes is given assigned to a specific aspect of the rehabilitation; strength, balance, speed, functional training and one day is for testing or group therapy. participants will be followed for four weeks, with testing on day one, after two weeks and at the last day of the four-week program.

the aim of this study is to investigate the effectiveness of our developed week-treatment program gapp (geriatric activation program pellenberg), on strength, balance, speed, functionality and cognition, with the main goal to achieve a better independence for adl. each day of the week an exercise program of 45 minutes is given assigned to a specific aspect of the rehabilitation. monday: speed and coordination, including as many repetitions as possible in one minute for: quick arm movements in standing, quick trunk movements in sitting, quick weight transfers in standing, stepping. tuesday: functional training, including walking stairs, transfers, sitting to lying and reverse, moving objects in the room, functional fit-o-meter. wednesday: balance, including maximum weight transfers in all directions, exercises with reduced base of support, reaching. thursday: strength, including sit to stand with a weight belt, lifting a weight bimanual of the table, walking with ankle weights, arm extension with therapy bands. friday: testing or group activity. one week the following test will be taken: berg balance scale, 10m walking test, digit symbol substitution test, knee extension and elbow extension strength with the microfet2, basic-adl and geriatric depression scale. the other week there will be a group session, this could be in sitting (like moving on music) or standing (like petanque). walking will be practiced every day of the week and individual needs (like specific hand rehabilitation or pain problems) will be addressed besides the program when needed.

Eligibility criteria:
inclusion criteria: * admitted to the geriatric rehabilitation ward of uz leuven, campus pellenberg * the ability to walk 10m with help of a person or walking aid * an expected stay of at least four weeks * a signed informed consent exclusion criteria: * medically instable * not able to understand the questions and tasks of the program or testing

Keywords: geriatric patients elderly multicomponent physical therapy
clinical feasibility of brain radiotherapy using synthetic cts in an mri-only workflow

Conditions: Brain Tumor, Primary; Brain Tumor - Metastatic

Summary: the goal of this observational study is to show the feasibility of an mri-only workflow in brain radiotherapy. the main question it aims to answer is: * is an mri-only workflow based on deep learning scts feasible in clinical routine? participants will be treated as in clinical routine, but treatment planning will be based on scts, that are generated from mri images. the dosimetrical equivalence to the standard ct based workflow will be tested at several points in the study.

the purpose of this clinical study is to investigate the clinical feasibility of a deep learning-based mri-only workflow for brain radiotherapy, that eliminates the registration uncertainty through calculation of a synthetic ct (sct) from mri data. a total of 54 patients with an indication for radiation treatment of the brain and stereotactic mask immobilization will be recruited. all study patients will receive standard therapy and imaging including both ct and mri. all patients will receive dedicated rt-mri scans in treatment position. an sct will be reconstructed from an acquired mri dixon-sequence using a commercially available deep learning solution on which subsequent radiotherapy planning will be performed. through multiple quality assurance (qa) measures and reviews during the course of the study, the feasibility of an mri-only workflow and comparative parameters between sct and standard ct workflow will be investigated holistically. these qa measures include feasibility and quality of image guidance (igrt) at the linear accelerator using sct derived digitally reconstructed radiographs in addition to potential dosimetric deviations between the ct and sct plan. the aim of this clinical study is to establish a brain mri-only workflow as well as to identify risks and qa mechanisms to ensure a safe integration of deep learning-based sct into radiotherapy planning and delivery.

Eligibility criteria:
inclusion criteria: * written informed consent * patient older than 18 years * tumor or metastases in the brain * immobilization with stereotactic mask * treatment on stereotactic linear accelerator (2.5 mm leafs) equipped with 2d/2d x-ray system exclusion criteria: * metal in the body, metal implants, pacemakers or other patient-specific factors that are a contraindication to an mri scan * metal implants, pacemakers or other patient-specific factors associated with increased risk from an mri scan * renal insufficiency (egfr \< 60 ml/min), allergy or other patient-specific factors that constitute a contraindication to contrast administration * renal insufficiency (egfr \< 60 ml/min), allergy or other patient-specific factors associated with an increased risk from contrast administration * patients who are institutionalized in care facilities, prisons or other supervised facilities. * patients under guardianship * non-consenting patients * pregnant or breastfeeding patients
children peritonitis ecology at chu de rennes - (iiapedia)

Conditions: Peritonitis

Summary: the main objectif is assess the germs (species + antibiograms) implicated in children intra-abdominal infections (community acquired or nosocomial ) at chu de rennes.


Eligibility criteria:
inclusion criteria: * children between 0 and 18 years old * intra-abdominal infection with and indication for surgery or radiologically guided drainage. * no opposition from the child or his parents exclusion criteria: * no microbiological sampling. * primitive peritonitis (spontaneous bacterial peritonitis, peritonitis during peritoneal dialysis)
a study to demonstrate the bioequivalence of rosiglitazone xr (brl-049653) 8mgs xr manufactured at two different sites.

Conditions: Alzheimer's Disease

Summary: the present pharmacokinetic study is designed to compare bioavailability and assess bioequivalence of two rosiglitazone xr formulations produced at two different sites.both formulations will be tested in fasting healthy volunteers


Eligibility criteria:
inclusion criteria: * healthy male or female aged 18-55 years. * bmi between 19 - 30 kg/m2 exclusion criteria: * liver function tests above the upper limit * excessive alcohol consumption history * history of cigarette smoking * positive hiv, hep b or c test * positive pregnancy test * history of heparin sensitivity * history of glucose intolerance

Keywords: alzheimers disease healthy volunteers bioequivalence
efficacy of ciclesonide versus budesonide in patients with asthma (18 to 75 y) (by9010/m1-137)

Conditions: Asthma

Summary: the aim of the study is to investigate the efficacy of ciclesonide versus budesonide on lung function, symptoms and use of rescue medication in patients with asthma. ciclesonide and budesonide will be inhaled once daily at one dose level each. the study duration consists of a baseline period (1 to 4 weeks) and a treatment period (12 weeks). the study will provide further data on safety and tolerability of ciclesonide.


Eligibility criteria:
main inclusion criteria: * during the last 4 weeks prior to baseline, treatment with an inhaled steroid (dosage: up to 250 mcg fluticasone propionate or equivalent) * fev1 80 - 105% of predicted * healthy with the exception of asthma * written informed consent has been obtained * outpatients * patients who have a history of persistent bronchial asthma for at least 6 months main exclusion criteria: * concomitant severe diseases or diseases which are contraindications for the use of inhaled steroids * concomitant copd (i.e. chronic bronchitis or emphysema) and/or other relevant lung diseases causing alternating impairment in lung function * an asthma exacerbation or an infection of the lower airways prior to entry into the baseline period * pregnancy * intention to become pregnant during the course of the study * breast feeding * lack of safe contraception * patient is current smoker with 10 or more pack-years * patient is ex-smoker with 10 or more pack-years

Keywords: asthma ciclesonide budesonide
effect of disconnecting pulmonary vagus nerve branch on chronic cough after unilateral thoracoscopic lobectomy

Conditions: Postoperative Chronic Cough

Summary: the purpose of this study was to determine whether disconnecting pulmonary vagus nerve branch can abatement chronic cough in patients undergoing unilateral thoracoscopic lobectomy,compared with preserving pulmonary vagus nerve branch.

after screening for the inclusion criteria and the exclusion criteria, 116 patients undergoing unilateral thoracoscopic lobectomy are randomly assigned to two groups, disconnecting pulmonary vague nerve branches and preserving pulmonary vague nerve branches. the incidence of chronic cough after surgery is compared between groups.

Eligibility criteria:
inclusion criteria: * patients with preoperative imaging of bronchial lung cancer below the secondary bronchus ,the maximum diameter of the tumor ≤ 5cm (t ≤ 2) and staging check not suggesting distant and mediastinal lymph node metastasis (n ≤ 1, m = 0) schedule to receive elective unilateral thoracoscopic lobectomy from 2019 to 2021 will be included in the trial. * asaⅰ-ⅲ exclusion criteria: * chronic cough (\>8 weeks), its causes including chronic bronchitis, asthma, gastroesophageal reflux disease, history of postnasal drip syndrome, and the use of acei drugs and so on; * other history of lung surgery; * patients with severe arrhythmia; * there are contraindications for anesthesia and surgery; * pregnancy and lactation.

Keywords: postoperative chronic cough pulmonary vagus nerve branch autonomic nervous system pulmonary nerves thoracoscopic lobectomy
investigation of serious adverse events following vaccination against yellow fever: emphasis on genetic basis and biological markers

Conditions: Drug-Related Side Effects and Adverse Reactions

Summary: it concerns an investigation aiming to investigate genetic biological(s) marker(s) which allow to identify individuals who have risk of serious adverse events to the yellow fever vaccine. this testing is free of hypothesis, because these markers are still unknown. there is no intervention, and it is not possible to establish primary and secondary outcomes.

the rational for the immunological study by latim is the observation made by the group that individuals vaccinated with the 17dd yellow fever vaccine show significant alterations on the levels of expression of genes such as clec5a, ifng, il6, rnasel, irf7, irf9, stat2 e oas1 (8). the study which will be conducted by the rockefeller university will be focused in the qualitative analysis of the genome and exome of volunteers. the study in latim will be focused in the quantitative analysis of mrna, which, together with the results of sequencing, may help in the search for biomarkers. as the expression of mrna is restricted to the acute phase of the adverse event, it will be done only during the first 30 days after the beginning of the adverse event.

Eligibility criteria:
inclusion criteria: * evidence of a systemic reaction in two or more organs within one month of vaccination with yellow fever vaccine; * laboratory evidence of yellow fever vaccine virus (at least one): positive culture for more than 7 days after vaccination; rt-pcr ≥ 3 log10 pfu/ml at any day after vaccination; positive rt-pcr more than 14 days after vaccination; presence of vaccine virus in tissue by culture, rt-pcr or immunohistochemistry. * laboratory exclusion of relevant differential diagnosis such as leptospirosis, viral hepatitis and arboviruses. * cases not obeying these strict criteria but that could be plausibly yel-avd or yel-and may be included, if approved by the investigator or co-investigators. exclusion criteria: * cases with adverse event after yellow fever vaccine not severe.

Keywords: yellow fever vaccine genetic factors viscerotropic disease neurological disease
repair of groin hernias after abdominal prostatectomy with robotic tapp

Conditions: Inguinal Hernia

Summary: this retrospective study investigates if robotic assisted groin hernia repair in patients who previously underwent abdominal prostatectomy has an equal or more favorable clinical outcome, compared to open repair in those patients.

in the personal practice of the investigators, there has been a decrease in open groin hernia repair from 17% to 6% since the introduction of robotic assisted surgery. this reflects a change in indication for complex hernias from an open to a minimal invasive approach. one of the typical indications for open approach before adopting the robotic platform were groin hernias after previous abdominal prostatectomy. since prostatectomy results in scarring of the retropubic area where we need to dissect during mis groin hernia repair, an open anterior approach is often suggested. with the enhanced view and instrument dexterity of the robotic platform, the investigators have now changed to a minimal invasive approach in these patients. therefore, this study will evaluate the clinical outcome after robotic assisted repair of groin hernias in patients who previously underwent an abdominal prostatectomy in comparison to open groin hernia repair.

Eligibility criteria:
inclusion criteria: * adult patients * underwent uni-or bilateral groin hernia repair in the period march 2015 - march 2020 * groin hernia repair via robotic assisted laparoscopy or open surgery * history of abdominal prostatectomy before the groin hernia repair exclusion criteria: * age below 18 * groin hernia repair via conventional laparoscopy * groin hernia repair via open surgery other than liechtenstein method * groin hernia repair without mesh placement
miltefosine plus il pentamidine for bolivian cl

Conditions: Leishmaniasis, Cutaneous

Summary: bolivian cutaneous leishmaniasis due to leishmania braziliensis was treated with the combination of miltefosine (150 mg/day for 28 days) plus intralesional pentamidine (120 ug/mm2 lesion area on days 1, 3, and 5).

bolivian cutaneous leishmaniasis due to leishmania braziliensis was treated with the combination of miltefosine (150 mg/day for 28 days) plus intralesional pentamidine (120 ug/mm2 lesion area on days 1, 3, and 5). efficacy and tolerance parameters were assessed. efficacy was assessed at 1, 3, and 6 months post therapy. tolerance was assessed on each day therapy was administered.

Eligibility criteria:
inclusion criteria: * one ulcerative lesion ≤ 900 mm2 in total area, * ≥ 12 years, * parasitologically diagnosed by visualization of amastigotes or culture of promastigotes from lesion material, * no antileishmanial therapy in the last 3 months, * no mucosal lesions, * no history of significant concomitant diseases including immunosuppression. exclusion criteria: